Skip Ribbon Commands
Skip to main content
Translate
Translate
menu iconMenu
search iconSearch

UC San Diego to Lead Nationwide Program in Pharmacogenomics

 

October 23, 2008  |  

The Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California, San Diego, will collaborate with the American Pharmacists Association, the American Society of Health-System Pharmacists, and the American Association of Colleges of Pharmacy (AACP) to promote PharmGenEd, in an educational campaign to more than 100,000 pharmacy practitioners and students across the country. 

The Pharmacogenomics Education Program: Bridging the Gap between Science and Practice” (PharmGenEd) is designed to educate pharmacists, students and other healthcare professionals in pharmacogenomics, the study of individual genetic differences in response to drug therapy.  

The project has been funded for just over $1 million for three years by the Centers for Disease Control and Prevention (CDC.)  The program team will work closely with the CDC to develop educational curriculum that focuses on basic pharmacogenomics concepts as well as their clinical applications, incorporating live and online methods including web-based virtual communities.

It is becoming increasingly clear that individuals respond differently to different medications, depending upon their genetic makeup, which impacts drug effectiveness and safety, as well as potential side effects. A key component of the program will “train the trainer” in methods to teach the next generation of pharmacists in this fast-moving field. 

The program’s principal investigator, Grace M. Kuo, PharmD, MPH, explains:  “The field of genomics and its scientific discoveries are developing at a dazzling pace.  Pharmacogenomics has a promising potential to increase the response rate of drug therapy and decrease the events of adverse drug reactions.  It may help us focus on safe and effective drug management to provide personalized medicine by choosing the most appropriate therapy for a particular patient.”

Currently, however, pharmacogenomics education materials are not readily available to healthcare professionals, and there appears to be a gap between healthcare providers’ knowledge and the expectations of patients regarding pharmacogenomics testing. 

“AACP recognizes that evidence-based and practice-relevant teaching resources for genomics and related areas are essential to assure that today’s students and tomorrow’s pharmacy practitioners can manage this aspect of their patients’ therapeutic plans,” said Lucinda Maine, Ph.D., Executive Vice President and CEO of AACP.

A major aim of the program is to increase awareness of the use of pharmacogenomic testing and its potential implications. “Typing major genes affecting drug action has become cost effective and various genetic tests have been developed,” said Kuo.  “We will explore how these testing tools can be used to improve pharmacotherapy and prevent adverse drug outcomes in real practice, based on scientific evidence.”

PharmGenEd can be a key to engaging pharmacists in understanding the appropriate use of genetic testing and the value that pharmacogenomics can have on patient care,” said Carol Abel, Director of Education for the American Pharmacists Association. 

This project will also acquaint practitioners of pharmacy and medicine with sequence differences in the genome and how they may influence therapeutic outcomes.  “The American Society of Health-System Pharmacists is pleased to support this important educational initiative,” said Henri R. Manasse, Jr., Ph.D., Sc.D., the organization’s CEO and executive vice president.  “Pharmacists practicing in hospitals and health systems need to take a lead role in educating patients about what pharmacogenomics means for their individual therapy.”

 “Pharmacogenomics is all about tailoring drug therapy to genetic information,” said Palmer Taylor, Ph.D., Dean of the Skaggs School and professor of pharmacology.  “Recent research advances not only link genotypes to differences in drug metabolism and disposition in the body, but also to differences in responsiveness of the sites at which drugs act.”  

Additional program core members are UC San Diego Skaggs School faculty members Kelly C. Lee, Pharm,.D, Joseph D. Ma, Pharm.D, James R. Halpert, Ph.D, Philip E. Bourne, Ph.D, and   Theodore Ganiats, M.D., of the School of Medicine.  Consultants include Karen S. Hudmon, Dr.PH,, MS, R.Ph.,Purdue University, and Magnus Ingelman-Sundberg, Ph.D., Karolinska Institute in Sweden.

# # #

Media Contact: Debra Kain, 619-543-6163, ddkain@ucsd.edu




Media Contact

Related News

4/22/2015
UC San Diego Health System and Scripps Health are partnering to provide improved continuity of patient care, fellowship training and research in hospice and palliative medicine. Under a new five-year ...
4/20/2015
Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have discovered a molecular mechanism that connects breast tissue stiffness to tumor metastasis and p ...
4/20/2015
A decrease in the amount of time spent eating and an increase in overnight fasting reduces glucose levels and may reduce the risk of breast cancer among women, report University of California, San Die ...
4/20/2015
The threat of falsified medications, also referred to as counterfeit, fraudulent, and substandard, can be quite real, yet the full scope and prevalence of the problem is poorly understood, say researc ...
4/17/2015
Researchers at the University of California, San Diego School of Medicine have created an in vitro, live-cell artificial vessel that can be used to study both the application and effects of devices us ...
4/16/2015
The increase in use of e-cigarettes has led to heated debates between opponents who question the safety of these devices and proponents who claim the battery-operated products are a useful cessation t ...
4/16/2015
An international team of scientists, led by researchers at University of California, San Diego School of Medicine, have found genetic overlap between Alzheimer’s disease (AD) and two significant cardi ...
4/13/2015
About one quarter of all atrial fibrillation patients at the lowest risk for stroke receive unnecessary blood thinners from cardiology specialists, according to a new study by researchers at Universit ...


Share This Article



Follow Us: